Dept, of Cancer Epidemiology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, China.
BMC Cancer. 2011 Aug 22;11:364. doi: 10.1186/1471-2407-11-364.
According to the very limited cancer registry, incidence and mortality rates for female breast cancer in China are regarded to be increasing especially in the metropolitan areas. Representative data on the breast cancer profile of Chinese women and its time trend over years are relatively rare. The aims of the current study are to illustrate the breast cancer profile of Chinese women in time span and to explore the current treatment approaches to female breast cancer.
This was a hospital-based nation-wide and multi-center retrospective study of female primary breast cancer cases. China was divided into 7 regions according to the geographic distribution; from each region, one tertiary hospital was selected. With the exception of January and February, one month was randomly selected to represent each year from year 1999 to 2008 at every hospital. All inpatient cases within the selected month were reviewed and related information was collected based on the designed case report form (CRF). The Cancer Hospital/Institute, Chinese Academy of Medical Sciences (CICAMS) was the leading hospital in this study.
Four-thousand two-hundred and eleven cases were randomly selected from the total pool of 45,200 patients and were included in the analysis. The mean age at diagnosis was 48.7 years (s.d. = 10.5 yrs) and breast cancer peaked in age group 40-49 yrs (38.6%). The most common subtype was infiltrating ductal carcinoma (86.5%). Clinical stage I & II accounted for 60.6% of 4,211 patients. Three-thousand five-hundred and thirty-four cases had estrogen receptor (ER) and progestin receptor (PR) tests, among them, 47.9% were positive for both. Two-thousand eight-hundred and forty-nine cases had human epidermal growth factor receptor 2(HER-2) tests, 25.8% of them were HER-2 positive. Among all treatment options, surgery (96.9% (4,078/4,211)) was predominant, followed by chemotherapy (81.4% (3,428/4,211). Much less patients underwent radiotherapy (22.6% (952/4,211)) and endocrine therapy (38.0% (1,599/4,211)).
The younger age of breast cancer onset among Chinese women and more advanced tumor stages pose a great challenge. Adjuvant therapy, especially radiotherapy and endocrine therapy are of great unmet needs.
根据非常有限的癌症登记数据，中国女性乳腺癌的发病率和死亡率被认为在不断上升，尤其是在大都市地区。关于中国女性乳腺癌特征及其多年来的时间趋势的代表性数据相对较少。本研究的目的是说明中国女性乳腺癌的特征，并探讨目前治疗女性乳腺癌的方法。
这是一项基于医院的全国多中心回顾性研究，纳入了女性原发性乳腺癌病例。中国根据地理位置分为 7 个区域；每个区域选择一家三级医院。除 1 月和 2 月外，每年在每家医院随机选择一个月来代表 1999 年至 2008 年的每一年。在所选择的月份内，对所有住院患者进行回顾性分析，并根据设计的病例报告表（CRF）收集相关信息。中国医学科学院肿瘤医院（CICAMS）是该研究的牵头医院。
从 45200 名患者的总样本中随机抽取 4211 例进行分析。诊断时的平均年龄为 48.7 岁（标准差=10.5 岁），乳腺癌发病高峰在 40-49 岁年龄组（38.6%）。最常见的亚型是浸润性导管癌（86.5%）。临床分期 I 期和 II 期占 4211 例患者的 60.6%。3534 例患者进行了雌激素受体（ER）和孕激素受体（PR）检测，其中 47.9%的患者两项均为阳性。2849 例患者进行了人表皮生长因子受体 2（HER-2）检测，其中 25.8%的患者 HER-2 阳性。在所有治疗方案中，手术（96.9%（4078/4211））占主导地位，其次是化疗（81.4%（3428/4211））。接受放疗（22.6%（952/4211））和内分泌治疗（38.0%（1599/4211））的患者较少。
中国女性乳腺癌发病年龄较轻，肿瘤分期较晚，这是一个巨大的挑战。辅助治疗，特别是放疗和内分泌治疗有很大的需求未得到满足。
